15-Year watch: tracking blood cancer patients after revolutionary cell therapy

NCT ID NCT06652633

Recruiting now Disease control Sponsor: Galapagos NV Source: ClinicalTrials.gov ↗

Summary

This study follows patients who received Galapagos CAR T-cell therapies for blood cancers to monitor their health for 15 years after treatment. Researchers want to understand the long-term safety of these therapies and track whether the modified cells remain in the body. The study will enroll 546 patients who previously received these treatments in earlier trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Academisch Medisch Centrum
RECRUITING

Amsterdam, 1105 AZ, Netherlands
Amsterdam UMC
RECRUITING

Amsterdam, 1081 HV, Netherlands
Antwerp University Hospital
RECRUITING

Edegem, 2650, Belgium
Centre Hospitalier Universitaire (CHU) De Liège
RECRUITING

Liège, 4032, Belgium
Hospital Clinic De Barcelona
RECRUITING

Barcelona, 08036, Spain
Leids University Medical Center (LUMC)
RECRUITING

Leiden, 2333 ZA, Netherlands

Conditions

Explore the condition pages connected to this study.

HEMATOLOGICAL MALIGNANCIES